401 related articles for article (PubMed ID: 33987350)
1. Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world.
Xie D; Sun Q; Wang X; Zhou J; Fan J; Ren Z; Gao Q
Ann Transl Med; 2021 Apr; 9(8):652. PubMed ID: 33987350
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of transarterial chemoembolization plus antiangiogenic- targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with portal vein tumor thrombus in the real world.
Feng JK; Liu ZH; Fu ZG; Chai ZT; Sun JX; Wang K; Cheng YQ; Zhu HF; Xiang YJ; Zhou LP; Shi J; Guo WX; Zhai J; Cheng SQ
Front Oncol; 2022; 12():954203. PubMed ID: 36505818
[TBL] [Abstract][Full Text] [Related]
3. Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors Versus Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma with First- or Lower-Order Portal Vein Tumor Thrombosis.
Zhang JX; Cheng Y; Wei J; Fan WL; Liu J; Zhou CG; Liu S; Shi HB; Chu XY; Zheng WL; Zu QQ
Cardiovasc Intervent Radiol; 2024 Apr; ():. PubMed ID: 38671322
[TBL] [Abstract][Full Text] [Related]
4. Role of Transarterial Chemoembolization in the Era of Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Combination Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score Matched Analysis.
Zhang JX; Hua HJ; Cheng Y; Liu S; Shi HB; Zu QQ
Acad Radiol; 2024 Apr; 31(4):1304-1311. PubMed ID: 37775449
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma.
Liu QQ; Wang XX; Ji H; Dou QY; Zhang HM
Med Oncol; 2024 Mar; 41(5):91. PubMed ID: 38526607
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma.
Wang YY; Yang X; Wang YC; Long JY; Sun HS; Li YR; Xun ZY; Zhang N; Xue JN; Ning C; Zhang JW; Zhu CP; Zhang LH; Yang XB; Zhao HT
World J Gastroenterol; 2023 Mar; 29(10):1614-1626. PubMed ID: 36970591
[TBL] [Abstract][Full Text] [Related]
7. Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.
Zhang W; Tong S; Hu B; Wan T; Tang H; Zhao F; Jiao T; Li J; Zhang Z; Cai J; Ye H; Wang Z; Chen S; Wang Y; Li X; Wang F; Cao J; Tian L; Zhao X; Chen M; Wang H; Cai S; Hu M; Bai Y; Lu S
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730273
[TBL] [Abstract][Full Text] [Related]
8. Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study.
Zhao L; Chang N; Shi L; Li F; Meng F; Xie X; Xu Z; Wang F
Heliyon; 2022 Jun; 8(6):e09538. PubMed ID: 35706954
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma: A Single Center Experience.
Pan X; Wu SJ; Tang Y; Zhou YF; Luo JW; Fang ZT
J Hepatocell Carcinoma; 2023; 10():883-892. PubMed ID: 37324411
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma.
Li J; Kong M; Yu G; Wang S; Shi Z; Han H; Lin Y; Shi J; Song J
Front Immunol; 2023; 14():1188308. PubMed ID: 37545497
[TBL] [Abstract][Full Text] [Related]
11. Transarterial chemoembolization with/without immune checkpoint inhibitors plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a single center, propensity score matching real-world study.
Yuan G; Li W; Zang M; Li R; Li Q; Hu X; Zhang Q; Huang W; Ruan J; Pang H; Chen J
Discov Oncol; 2024 Mar; 15(1):68. PubMed ID: 38460053
[TBL] [Abstract][Full Text] [Related]
12. The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study.
Cao F; Yang Y; Si T; Luo J; Zeng H; Zhang Z; Feng D; Chen Y; Zheng J
Front Oncol; 2021; 11():783480. PubMed ID: 34988019
[TBL] [Abstract][Full Text] [Related]
13. Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma.
Huang JT; Zhong BY; Jiang N; Li WC; Zhang S; Yin Y; Yang J; Shen J; Wang WS; Zhu XL
J Hepatocell Carcinoma; 2022; 9():1217-1228. PubMed ID: 36474670
[TBL] [Abstract][Full Text] [Related]
14. A Retrospective Study on Therapeutic Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors Plus Lenvatinib in Patients With Unresectable Hepatocellular Carcinoma.
Teng Y; Ding X; Li W; Sun W; Chen J
Technol Cancer Res Treat; 2022; 21():15330338221075174. PubMed ID: 35313780
[No Abstract] [Full Text] [Related]
15. Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review.
Sun L; Xu X; Meng F; Liu Q; Wang H; Li X; Li G; Chen F
Front Oncol; 2022; 12():980214. PubMed ID: 36249023
[TBL] [Abstract][Full Text] [Related]
16. Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study.
Cai M; Huang W; Liang W; Guo Y; Liang L; Lin L; Xie L; Zhou J; Chen Y; Cao B; Wu J; Zhu K
Liver Int; 2024 Apr; 44(4):920-930. PubMed ID: 38291865
[TBL] [Abstract][Full Text] [Related]
17. Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study.
Wu XK; Yang LF; Chen YF; Chen ZW; Lu H; Shen XY; Chi MH; Wang L; Zhang H; Chen JF; Huang JY; Zeng YY; Yan ML; Zhang ZB
EClinicalMedicine; 2024 Jan; 67():102367. PubMed ID: 38169778
[TBL] [Abstract][Full Text] [Related]
18. Addition of transarterial chemoembolization improves outcome of tyrosine kinase and immune checkpoint inhibitors regime in patients with unresectable hepatocellular carcinoma.
Hu Y; Pan T; Cai X; He QS; Zheng YB; Huang MS; Jiang ZB; Chen JW; Wu C
J Gastrointest Oncol; 2023 Aug; 14(4):1837-1848. PubMed ID: 37720446
[TBL] [Abstract][Full Text] [Related]
19. Transarterial Chemoembolization Plus Lenvatinib and PD-1 Inhibitors for Hepatocellular Carcinoma with Main Trunk Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.
Li SQ; Wu JY; Wu JY; Xie H; Li JH; Zeng ZX; Fu YK; Liu DY; Li H; Chen WZ; Huang JY; Yan ML
J Hepatocell Carcinoma; 2023; 10():1799-1811. PubMed ID: 37850080
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma.
Yang F; Yang J; Xiang W; Zhong BY; Li WC; Shen J; Zhang S; Yin Y; Sun HP; Wang WS; Zhu XL
Front Oncol; 2021; 11():657512. PubMed ID: 35096555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
